Humacyte HUMA 深 沪
等待开盘 10-08 09:30:00 美东时间
0.4723
-0.006
-1.19%
华盛通- 最 高0.4799
- 今 开0.4792
- 成交量 391.29万股
- 最 低 0.46
- 昨 收 0.478
- 总市值 1.31亿
- 52周最高 1.895
- 市盈率 静 --
- 换手率 1.41%
- 52周最低 0.46
- 委 比 88.24%
- 总股本 2.78亿
- 历史最高 17.45
- 量 比 0.79
- 振 幅 4.16%
- 历史最低 0.46
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多估值跌至十年低点！巴克莱首次覆盖26家美股医疗科技股，首选史赛克(SYK.US)等
巴克莱分析师Christopher Pasquale周二首次覆盖26家美股医疗科技公司，并将史赛克(SYK.US)和雅培(ABT.US)列入大盘医疗科技股推荐名...
今天 13:58
美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
今天 12:30
Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5
Barclays analyst Christopher Pasquale initiates coverage on Humacyte (NASDAQ:HUMA) with a Equal-Weight rating and announces Price Target of $0.5.
10-07 20:45
Humacyte Bolsters Board for Upcoming Commercial Expansion
Humacyte ( ($HUMA) ) has shared an announcement. On September 22, 2026, Humacyt...
09-29 05:14
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte, Inc. has announced the addition of Scott Coward and Paul Kuznik to its Board of Directors. Both bring extensive experience in commercialization, leadership, and global operations. Coward, formerly with Exact Sciences, has expertise in public company governance and legal affairs. Kuznik, a veteran in vascular healthcare, has led commercialization efforts in cardiovascular devices. Their加入 is expected to support Humacyte's ongoing product...
09-28 12:00
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Humacyte, Inc. announced that its CEO, Laura Niklason, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 16, 2026, at 11:00am ET. Management will also hold one-on-one meetings. The event will be webcast and a replay will be available on the company's website. Humacyte is developing bioengineered human tissues, including ATEVs, which have received FDA approval and are in la...
09-10 12:00
Humacyte Receives FDA Authorization To Extend The Expiration Dating Period For Symvess From 18 To 36 Months
Extension for Symvess (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months when stored refrigerated at 2°C to 8°C (36°F to 46°F). The expiration dating extension is supported by additional stability data demonstrating that Symvess continues to meet all established product q...
09-09 20:06
Humacyte Confirms Plans For ATEV Supplemental BLA Filing
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase 3 studies of ATEV, including results from V012 dialysis access study in women – – The V012 dialysis ...
08-24 20:03
美股牛股 | Moderna狂飙177%！美银火速将其目标价翻两番；油气股SOC升近20%
Moderna狂飙177%！美银火速将其目标价翻两番，TEM、BNTX受利好分别升24%、22%；；油气股SOC升近20%，法院裁定其加州管道重启工作将继续进行>>
08-20 16:20
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
Humacyte's Symvess, the first FDA-approved bioengineered human blood vessel, is now being used in Arizona by Dr. Jeromy Brink, a vascular surgeon at Banner University Medical Center in Phoenix. Symvess is an off-the-shelf solution for urgent revascularization in adults with extremity arterial injury, eliminating the need to harvest veins from patients. Dr. Brink, who has performed four implants since gaining access two weeks ago, calls Symvess th...
08-18 12:00
